Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 5/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14963998 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL16983769 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL37833 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL6046844 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905722 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905700 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL379163 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL1870550 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905404 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL4960230 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4204442-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022046747-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-105001140-A | Preparation method and application of fatty dioic acid derivative | ZHUHAI UNITED LAB CO LTD | 2015-10-28 | — | — | CN | disclosed |
| US-20060160741-A1 | Dimeric TF antagonists | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| US-20030229018-A1 | Dimeric TF antagonist | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160741-A1 | Dimeric TF antagonists | TFPI, TFPI2, F2 | SMN1; SMN2 4502/4885KMT2A 3324/4885HPGD 2933/4885 |
| US-20030229018-A1 | Dimeric TF antagonist | F2, TFPI, TFPI2 | SMN1; SMN2 4319/4885KMT2A 2831/4885HPGD 2799/4885 |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | SMN1; SMN2 3416/4885KMT2A 4174/4885HPGD 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.